The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.

BMC Cancer · 2015 · PMC4445981 · PMID 25981639

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While these effects did not reach statistical significance, DL-TBOA also tended to increase pRb levels under control conditions in both parental cell lines, and slightly but consistently decreased pRb levels after oxaliplatin treatment in all cell types except oxaliplatin-resistant HCT116 cells.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.